DCF Advisers LLC Acquires 500 Shares of Prothena Co. plc (NASDAQ:PRTA)

DCF Advisers LLC grew its holdings in shares of Prothena Co. plc (NASDAQ:PRTA) by 0.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,500 shares of the biotechnology company’s stock after buying an additional 500 shares during the quarter. Prothena accounts for about 1.1% of DCF Advisers LLC’s holdings, making the stock its 28th biggest position. DCF Advisers LLC owned approximately 0.20% of Prothena worth $2,219,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in PRTA. Signaturefd LLC boosted its stake in Prothena by 182.1% during the 2nd quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 863 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Prothena by 265.9% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,544 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,122 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Prothena during the first quarter valued at approximately $96,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Prothena by 13.1% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company’s stock worth $211,000 after buying an additional 1,186 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in Prothena in the 4th quarter valued at $222,000. 97.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on PRTA. Royal Bank of Canada cut their price objective on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Oppenheimer cut their price target on shares of Prothena from $66.00 to $62.00 and set an “outperform” rating on the stock in a report on Wednesday, August 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a research note on Monday, August 12th. Finally, StockNews.com upgraded Prothena from a “sell” rating to a “hold” rating in a research note on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $62.86.

Prothena Stock Up 0.8 %

PRTA opened at $21.66 on Friday. Prothena Co. plc has a twelve month low of $18.69 and a twelve month high of $55.89. The company’s 50-day moving average price is $21.80 and its two-hundred day moving average price is $22.31. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -6.66 and a beta of 0.18.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $1.22 EPS for the quarter, beating the consensus estimate of ($1.01) by $2.23. Prothena had a negative return on equity of 9.00% and a negative net margin of 23.44%. The business had revenue of $132.01 million for the quarter, compared to the consensus estimate of $10.73 million. During the same quarter in the prior year, the business earned ($1.03) earnings per share. Prothena’s revenue for the quarter was up 3184.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Prothena Co. plc will post -2.31 earnings per share for the current year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.